Injection site rotation on a GLP-1: the lump nobody warned you about

Ask someone six months into a weekly GLP-1 where they inject and the answer is remarkably consistent. On the left side, about two inches from the navel, because that is where it hurt least the first time. Ask whether they move it and the answer is usually that they alternate left and right, or that they had not really thought about it.

Then, sometimes, a different conversation starts. The dose that was working seems to be doing less. The response feels inconsistent week to week without any change in dose or routine. And if you ask the patient to run a flat palm across the area they have been using, they find something: a slightly raised, slightly firmer, slightly rubbery patch that is not tender and that they had noticed vaguely and dismissed.

The original element in this piece is an eight site, eight week rotation map with a monthly two minute palpation self check, adapted deliberately from insulin injection practice, with the adaptation and its limits stated openly. No GLP-1 manufacturer publishes a rotation grid, because the tissue complication that drives rotation guidance was characterized in insulin users and the evidence in weekly weight management injections has not caught up. That gap is the honest starting point rather than something to paper over.

What lipohypertrophy actually is. Repeated injection into the same small patch of subcutaneous tissue changes the tissue. The recognized end result in insulin users is lipohypertrophy: a thickened, often slightly raised area of fatty tissue that feels firmer than the skin around it and is frequently less sensitive, which is exactly why patients gravitate to it. It is easier to inject into a numb lump than into fresh tissue, so the habit is self reinforcing.

The complication is not cosmetic. Absorption from an altered site is erratic. In insulin, this produces unpredictable glycemic control, and it is well enough established that injection technique recommendations treat site rotation as a core safety instruction rather than a nicety. A multinational set of insulin delivery recommendations puts rotation and needle practice at the center of the guidance. The Lipohypertrophy Monitoring Study went further and looked at whether education about rotation combined with single use needles improved control, and the results were sobering enough that the authors described their own finding as an unpleasant truth, which is a useful reminder that knowing the rule and following it are different things.

There is also direct tissue evidence rather than just outcome evidence. An ultrasonographic and histological evaluation of repeated injection without site rotation documented measurable changes in skin thickness at the sites involved. Something structural is happening in the tissue, and it is visible on imaging.

Why this transfers to GLP-1 use, and where the transfer is uncertain. The mechanical situation is genuinely similar. Both are subcutaneous injections. Both use fine needles. Both are self administered on a fixed schedule for years rather than months. Both have manufacturer approved sites that are the same three regions: abdomen, thigh and upper arm.

Two differences cut the other way, and they cut in the patient's favor. Frequency is the big one. Most GLP-1 regimens are weekly rather than multiple times daily, which is one to two orders of magnitude fewer injections into the same tissue over the same period. Volume per injection is also typically small. So the exposure is far lower, and it would be wrong to imply that a weekly injector faces the risk profile of someone taking four insulin doses a day.

What does not differ is the human behavior. People find the comfortable spot and stay in it, and years of weekly injections into a patch the size of a coin is still years.

The eight site, eight week map. Divide the approved regions into eight zones and use each one once before returning to the first. Right lower abdomen, left lower abdomen, right upper abdomen, left upper abdomen, right outer thigh, left outer thigh, right upper outer arm, left upper outer arm. Written on a note in your phone with the date next to each, that is the whole system, and it takes ten seconds a week.

Two refinements matter. Within a zone, do not use the same square inch twice. Shift by at least a finger width each time you come back around, so that over a year a zone is a patch rather than a point. And keep well clear of the navel, roughly two inches, which is standard guidance for abdominal injection generally.

If you use different regions, know that absorption rates differ between the abdomen, thigh and arm, and that this is a documented difference in insulin rather than a theoretical one. For a weekly medication with a long half life the practical consequence is small, but if you are someone who tracks side effect timing carefully, expect a slightly different feel in the first day or two when you change region, and do not read it as the drug failing.

The monthly palpation check. Once a month, in good light, run the flat pads of three fingers slowly over each zone you have used, pressing lightly. You are feeling for anything raised, firm, rubbery or oddly smooth compared with the tissue beside it. Compare left to right, which is the fastest way to detect a change, since most people are roughly symmetrical. Also look at the area with light coming across it from the side rather than from above, because a subtle raised patch shows as a shadow long before it is obvious face on.

If you find something, stop using that zone and tell your prescriber at the next visit. Do not inject into it because it is comfortable. Comfort is the symptom, not the reassurance.

What the studies do not tell you. There is no published prevalence figure for lipohypertrophy in GLP-1 users. Not a low number, no number. There is no trial establishing that rotation improves outcomes in weekly weight management injections, no imaging series characterizing tissue change at those sites, and no guidance document specifying a rotation interval for this class. Everything above is extrapolated from insulin, and extrapolation across a hundredfold difference in injection frequency is a real limitation that anyone repeating this advice should state.

What is known is the direction. The tissue mechanism is not drug specific, it is injection specific. The cost of rotating is zero. The cost of not rotating, if the mechanism transfers even partially, is erratic absorption of a medication whose whole value depends on steady levels, and erratic absorption is easy to misread as a plateau or as the dose no longer working.

The takeaway. If you have been injecting into the same comfortable spot since your first pen, go feel it now, and start the eight zone list this week. It costs nothing, it is the single easiest thing on the whole list of things that can go sideways on these medications to prevent, and the only reason it is not standard advice is that the evidence base for this drug class is young rather than that the concern is unfounded. Raise it at your next visit alongside the rest of your injection and storage routine.